Bioprinting is not cheap.

Bioprinting promises on-demand organs, but the reality is costly. From expensive bioinks and failed prints to clinical translation hurdles, every step demands significant financial and scientific investment. Recognizing these costs upfront is critical for setting realistic expectations, attracting sustainable funding, and driving meaningful progress in the field.